Treatment in Esophagogastric Junction Cancer: Past, Present and Future

Publication date: Available online 20 September 2019Source: Cirugía Española (English Edition)Author(s): Carles Pericay, Ismael Macías-Declara, Virginia Arrazubi, Laia Vilà, Miguel MarínAbstractAdenocarcinomas of the gastroesophageal junction represent 27% of all gastric tumors. In recent years, it has been classified as an entity of its own, with specific treatments that are sometimes differentiated from gastric treatments. Treatment can be based on chemotherapy (CTx) or chemoradiotherapy (CRTx) that is administered preoperatively (neoadjuvant), postoperatively (adjuvant) or perioperatively. There are studies that have tested several treatment modalities, but there is currently no single protocolized sequence. The results point to an improvement in survival when we administer preoperative treatment, with evidence in favor of CRTx and CTx. Studies are already underway with targeted treatment that aim to increase the activity of traditional chemotherapy. In the next few years, we should know the role of immunotherapy in this group of patients.ResumenLos adenocarcinomas de la unión esofagogástrica representan un 27% de todos los tumores gástricos. En los últimos años se está clasificando como una entidad propia, con tratamientos específicos y en ocasiones diferenciados de los tratamientos de los adenocarcinomas de cuerpo gástrico. El esquema de tratamiento puede basarse en quimioterapia (QT) o quimiorradioterapia (QTRT), que se administra de forma preoperatoria (ne...
Source: Cirugia Espanola - Category: Surgery Source Type: research